Annals of Oncology published full results from the pivotal investigational Phase III PEACE III trial, evaluating XOFIGO® (radium-223 dichloride) in combination with enzalutamide, an AR pathway inhibitor (ARPI), versus enzalutamide alone in the first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.
From mental health concerns to fertility preservation, adolescents and young adults with cancer require a specialized approach to treatment and survivorship care. In honor of Childhood Cancer Awareness Month, ACCC highlights a pivotal program from the University of North Carolina Lineberger Comprehensive Cancer Center and resources that meet the critical needs of these patients.
